Impact Factor
3.65
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.99
1,663 total citations
h5-index
43
h5 depth signal
Cited share
74.1%
431 of 582
Total citations
1,663
Citation footprint
Metric signal
2.68
External metric anchor
Self-citation
3.6%
60 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
847
Italy
424
China
414
Canada
390
Netherlands
349
Citing Fields of Research
Hematology
3,126
Cardiology
909
Oncology
539
Clinical Laboratory Science
272
Immunology
244
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
20,206
Articles tracked across the journal lifetime
Indexed publication set
582
431 cited publications
Last 12 months
289
24.1 publications/month
Open access share
24.2%
70 OA publications in the last year
Leading citing country
United States
847 citing publications
Leading citing field
Hematology
3,126 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v4n1,Jan. 1974-
v4n1,Jan. 1974-
Active Coverage
Research Focus & Classification
Indexed Subjects
Hematology
Broad Categories
Vascular Diseases
Hematology
MeSH Descriptors
Hemorrhage
Hemostasis
Thrombosis
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.thromres.2026.109895
Open DOI
Mental health in venous thromboembolism: A scoping review of the qualitative and quantitative evidence
02
DOI 10.1016/j.thromres.2026.109893
Open DOI
Apixaban for thromboprophylaxis in paediatric cardiology patients: Real-world data from a single institution
03
DOI 10.1016/j.thromres.2026.109871
Open DOI
Real-world data of extended half-life factor VIII prophylaxis in patients with hemophilia A: A multicenter retrospective cohort study
04
DOI 10.1016/j.thromres.2026.109892
Open DOI
Predictive performance of bleeding risk scores for extended anticoagulation in pulmonary embolism: Insights from the CURES-2 registry
05
DOI 10.1016/j.thromres.2026.109869
Open DOI
Incidence and prognostic impact of venous thromboembolism in a prospective single-center cohort of patients with cancer: The THEO study
06
DOI 10.1016/j.thromres.2026.109870
Open DOI
Complement activation characterizes a high mortality subgroup in pulmonary embolism: An observational proteomic study
07
DOI 10.1016/j.thromres.2026.109868
Open DOI
Limitations of protamine sulphate for in vitro neutralisation of unfractionated heparin in thrombin generation assays
08
DOI 10.1016/j.thromres.2026.109860
Open DOI
From APICAT to APICath?
09
DOI 10.1016/j.thromres.2026.109867
Open DOI
Prospective pilot case series of off-label use of apixaban in patients with localized intravascular coagulopathy
10
DOI 10.1016/j.thromres.2026.109866
Open DOI
The calf clot of the lungs: Detection, overdiagnosis, and structured surveillance in isolated subsegmental pulmonary embolism
Bibliographical & Catalog Notes
Has supplement: Thrombosis research. Supplement, 1974- .
Some v. accompanied by supplements, 1992- .
Also issued online.
Indexes: Vols. 1-5, 1972-74. 1 v; Vols. 6-10, 1975-77. 1 v; Vols. 25-32, 1982-83. 1 v. (Includes index to Thrombosis research. Supplement, 4-5, 1983).
Complemented by (work): Thrombosis update 2666-57278 (OCoLC)1232531635 (DNLM)9918249114406676.
Vol. 28, no. 1 (1982)19921002 Notice published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper